Watch BEAM. Know when insiders buy.
One email the day a filing lands. Free.
BEAM
Beam Therapeutics Inc.
24.84
−0.09 −0.36%
USD · Oct 21, 07:40 p.m. ET
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
31
FLAG · insiders 25, shorts 36
Insiders, 90 days
−$1.2M
net selling · 0 buys, 3 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
1 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.6BP/E —DIV YIELD —FCF YIELD -14.53%REV TTM $156M +158.9%NET INCOME −$85.4MNET CASH $119.6M52W 20.60 – 37.92NEXT EARNINGS Nov 3 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $490K | −94.2% | — | −$126.6M | −$122.7M | — | -1.18 | −$66.1M | $2.4M | −$68.5M | Aug 4 |
| Q1 2026 · Mar 31 | $31.7M | +324.9% | — | −$107.2M | −$94.3M | — | -0.91 | −$128.5M | $2.2M | −$130.7M | Aug 4 |
| Q4 2025 · Dec 31derived | $114.1M | +279.5% | — | −$17.4M | $244.3M | — | 2.51 | −$83.3M | $3.7M | −$87M | Feb 24 |
| Q3 2025 · Sep 30 | $9.7M | −32.0% | — | −$126.8M | −$112.7M | — | -1.10 | −$81.5M | $5M | −$86.5M | Nov 4 |
| Q2 2025 · Jun 30 | $8.5M | −28.1% | — | −$120.2M | −$102.1M | — | -1.00 | −$76.5M | $3.1M | −$79.6M | Aug 4 |
| Q1 2025 · Mar 31 | $7.5M | +0.8% | — | −$119.3M | −$108.3M | — | -1.23 | −$103.9M | $3.1M | −$106.9M | Aug 4 |
| Q4 2024 · Dec 31derived | $30.1M | −90.5% | — | −$100M | −$90.4M | −163.3% | -1.09 | −$76.4M | $3M | −$79.3M | Feb 24 |
| Q3 2024 · Sep 30 | $14.3M | −17.0% | — | −$106.5M | −$96.7M | — | -1.17 | −$88.1M | $1.6M | −$89.7M | Nov 4 |
| Q2 2024 · Jun 30 | $11.8M | — | — | −$104.9M | −$91.1M | — | -1.11 | −$83M | $2M | −$85M | Nov 4 |
| Q1 2024 · Mar 31 | $7.4M | — | — | −$104.1M | −$98.7M | — | -1.21 | −$99.7M | $2.4M | −$102.2M | Nov 4 |
| Q4 2023 · Dec 31derived | $316.2M | — | — | $132.9M | $142.8M | — | 1.91 | $135.1M | $3.6M | $131.5M | Feb 24 |
| Q3 2023 · Sep 30 | $17.2M | — | — | −$108.3M | −$96.1M | — | -1.22 | −$89.8M | $7.9M | −$97.7M | Nov 5 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $139.7M | — | −$383.7M | −$80M | -57.2% | -0.81 | −$345.1M | $14.9M | −$360M | — | — |
| FY2024 · to Dec 31 | $63.5M | — | −$415.6M | −$376.7M | -593.1% | -4.58 | −$347.2M | $8.9M | −$356.2M | — | — |
| FY2023 · to Dec 31 | $377.7M | — | −$176.5M | −$132.5M | -35.1% | -1.72 | −$149.2M | $33.7M | −$182.9M | — | — |
| FY2022 · to Dec 31 | $60.9M | — | −$338.5M | −$289.1M | -474.5% | -4.13 | $22.5M | $49M | −$26.4M | — | — |
| FY2021 · to Dec 31 | $51.8M | — | −$392.5M | −$370.6M | -714.9% | -5.77 | −$66.3M | $46.8M | −$113.1M | — | — |
| FY2020 · to Dec 31 | $24K | — | −$132.8M | −$194.6M | -810800.0% | -4.19 | −$95.7M | $16.4M | −$112.1M | — | — |
Every number comes from Beam Therapeutics Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.